These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
155 related items for PubMed ID: 7915909
1. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Nicoletti MI, Lucchini V, D'Incalci M, Giavazzi R. Eur J Cancer; 1994; 30A(5):691-6. PubMed ID: 7915909 [Abstract] [Full Text] [Related]
2. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. Nicoletti MI, Lucchini V, Massazza G, Abbott BJ, D'Incalci M, Giavazzi R. Ann Oncol; 1993 Feb; 4(2):151-5. PubMed ID: 8095399 [Abstract] [Full Text] [Related]
3. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Massazza G, Tomasoni A, Lucchini V, Allavena P, Erba E, Colombo N, Mantovani A, D'Incalci M, Mangioni C, Giavazzi R. Int J Cancer; 1989 Sep 15; 44(3):494-500. PubMed ID: 2777413 [Abstract] [Full Text] [Related]
4. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Dykes DJ, Bissery MC, Harrison SD, Waud WR. Invest New Drugs; 1995 Sep 15; 13(1):1-11. PubMed ID: 7499102 [Abstract] [Full Text] [Related]
5. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Valoti G, Nicoletti MI, Pellegrino A, Jimeno J, Hendriks H, D'Incalci M, Faircloth G, Giavazzi R. Clin Cancer Res; 1998 Aug 15; 4(8):1977-83. PubMed ID: 9717828 [Abstract] [Full Text] [Related]
6. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI, Giavazzi R. Clin Cancer Res; 2003 Aug 15; 9(9):3476-85. PubMed ID: 12960140 [Abstract] [Full Text] [Related]
7. Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer. Boven E, Venema-Gaberscek E, Erkelens CA, Bissery MC, Pinedo HM. Ann Oncol; 1993 Apr 15; 4(4):321-4. PubMed ID: 8100146 [Abstract] [Full Text] [Related]
8. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Tanaka M, Obata T, Sasaki T. Eur J Cancer; 1996 Feb 15; 32A(2):226-30. PubMed ID: 8664032 [Abstract] [Full Text] [Related]
9. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Vanhoefer U, Cao S, Harstrick A, Seeber S, Rustum YM. Ann Oncol; 1997 Dec 15; 8(12):1221-8. PubMed ID: 9496387 [Abstract] [Full Text] [Related]
10. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH. Gynecol Oncol; 2003 Feb 15; 88(2):130-5. PubMed ID: 12586591 [Abstract] [Full Text] [Related]
11. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Giavazzi R, Garofalo A, Ferri C, Lucchini V, Bone EA, Chiari S, Brown PD, Nicoletti MI, Taraboletti G. Clin Cancer Res; 1998 Apr 15; 4(4):985-92. PubMed ID: 9563894 [Abstract] [Full Text] [Related]
12. Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes Ed, Steger M, Nelson-Taylor T, Vincent M, Rogers R, Atkinson EN, Kavanagh JJ. J Clin Oncol; 2000 Jul 15; 18(14):2733-9. PubMed ID: 10894873 [Abstract] [Full Text] [Related]
13. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. Sharma A, Straubinger RM, Ojima I, Bernacki RJ. J Pharm Sci; 1995 Dec 15; 84(12):1400-4. PubMed ID: 8748320 [Abstract] [Full Text] [Related]
14. Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity. Burbridge MF, Kraus-Berthier L, Naze M, Pierre A, Atassi G, Guilbaud N. Int J Oncol; 1999 Dec 15; 15(6):1155-62. PubMed ID: 10568822 [Abstract] [Full Text] [Related]
15. The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts. Braakhuis BJ, Kegel A, Welters MJ. Cancer Lett; 1994 Jun 30; 81(2):151-4. PubMed ID: 7912164 [Abstract] [Full Text] [Related]
16. Risks and benefits of taxanes in breast and ovarian cancer. Michaud LB, Valero V, Hortobagyi G. Drug Saf; 2000 Nov 30; 23(5):401-28. PubMed ID: 11085347 [Abstract] [Full Text] [Related]
17. The taxoids. Comparative clinical pharmacology and therapeutic potential. Eisenhauer EA, Vermorken JB. Drugs; 1998 Jan 30; 55(1):5-30. PubMed ID: 9463787 [Abstract] [Full Text] [Related]
18. Docetaxel in the treatment of ovarian cancer. Kavanagh JJ. Oncology (Williston Park); 2002 Jun 30; 16(6 Suppl 6):73-81. PubMed ID: 12108900 [Abstract] [Full Text] [Related]
19. [Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice]. Shakuto S, Fujita F, Fujita M. Gan To Kagaku Ryoho; 2006 Mar 30; 33(3):337-43. PubMed ID: 16531714 [Abstract] [Full Text] [Related]
20. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J. Health Technol Assess; 2000 Mar 30; 4(17):1-113. PubMed ID: 11074389 [Abstract] [Full Text] [Related] Page: [Next] [New Search]